Clinical Features of Patients with Home Isolation Sars-Cov-2 Infection: A Multicenter Retrospective Study in Southern Italy
Abstract
:1. Introduction
2. Methods
2.1. Study Design and Setting
2.2. Variables and Definitions
2.3. Statistical Analysis
3. Results
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062. [Google Scholar] [CrossRef]
- Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X.; Liu, L.; Shan, H.; Lei, C.L.; Hui, D.S.C.; et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020, 382, 1708–1720. [Google Scholar] [CrossRef] [PubMed]
- Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020, 323, 1061–1069. [Google Scholar] [CrossRef] [PubMed]
- How COVID-19 Spreads 2020. Available online: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html (accessed on 11 November 2020).
- WHO-2019-nCoV-Sci_Brief-Transmission_modes-2020.3-eng. Available online: https://www.scribd.com/document/469436416/WHO-2019-nCoV-Sci-Brief-Transmission-modes-2020-3-eng (accessed on 9 July 2020).
- Galbadage, T.; Peterson, B.M.; Gunasekera, R.S. Does COVID-19 Spread through droplets alone? Front. Public Health 2020, 8, 163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, Q.; Guan, X.; Wu, P.; Qun, L.; Xuhua, G.; Peng, W.; Xiaoye, W.; Lei, Z.; Yeqing, T.; Ruiqi, R.; et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus—Infected pneumonia. N. Engl. J. Med. 2020, 382, 1199–1207. [Google Scholar] [CrossRef] [PubMed]
- Lauer, S.A.; Grantz, K.H.; Bi, Q.; Jones, F.K.; Zheng, Q.; Meredith, H.R.; Azman, A.S.; Reich, N.G.; Lessler, J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. Ann. Intern. Med. 2020, 172, 577–582. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, L.; Huang, T.; Wang, Y.; Wang, Z.; Liang, Y.; Huang, T.; Zhang, H.; Sun, W.; Wang, Y. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J. Med. Virol. 2020, 92, 577–583. [Google Scholar] [CrossRef] [PubMed]
- Symptoms of COVID-19. Available online: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html (accessed on 22 February 2021).
- Macera, M.; De Angelis, G.; Sagnelli, C.; Coppola, N.; Vanvitelli COVID-19 group. Clinical Presentation of COVID-19: Case Series and Review of the Literature. Int. J. Environ. Res. Public Health 2020, 17, 5062. [Google Scholar] [CrossRef] [PubMed]
- Wu, Z.; McGoogan, J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases from the Chinese Center for Disease Control and Prevention. JAMA 2020, 323, 1239–1242. [Google Scholar] [CrossRef] [PubMed]
- Kim, G.-U.; Kim, M.-J.; Ra, S.; Lee, J.; Bae, S.; Jung, J.; Kim, S.-H. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin. Microbiol. Infect. 2020, 26, 948.e1–948.e3. [Google Scholar] [CrossRef] [PubMed]
- Società Italiana di Malattie Infettive. Available online: www.simit.org/simit/sezioni-regionali/campania (accessed on 8 March 2021).
- Ayaz, C.M.; Dizman, G.T.; Metan, G.; Alp, A.; Unal, S. Out-patient management of patients with COVID-19 on home isolation. Infez Med. 2020, 28, 351–356. [Google Scholar] [PubMed]
- Marfella, R.; Paolisso, P.; Sardu, C.; Bergamaschi, L.; D’Angelo, E.C.; Barbieri, M.; Rizzo, M.R.; Messina, V.; Maggi, P.; Coppola, N.; et al. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. Diabetes Metab. 2020, 46, 403–405. [Google Scholar] [CrossRef] [PubMed]
- Polverino, F.; Stern, D.A.; Ruocco, G.; Balestro, E.; Bassetti, M.; Candelli, M.; Cirillo, B.; Contoli, M.; Corsico, A.; D’Amico, F.; et al. Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO). Front. Cardiovasc. Med. 2020, 7, 585866. [Google Scholar] [CrossRef] [PubMed]
- Mottola, F.F.; Verde, N.; Ricciolino, R.; Di Mauro, M.; Migliaccio, M.G.; Carfora, V.; Spiniello, G.; Coppola, N.; Vanvitelli COVID-19 group. Cardiovascular System in COVID-19: Simply a Viewer or a Leading Actor? Life 2020, 10, 165. [Google Scholar] [CrossRef]
- Al Hayek, A.A.; Robert, A.A.; Alotaibi, Z.K.; Al Dawish, M. Clinical characteristics of hospitalized and home isolated COVID-19 patients with type 1 diabetes. Diabetes Metab. Syndr. Clin. Res. Rev. 2020, 14, 1841–1845. [Google Scholar] [CrossRef]
- Ebert, T.J.; Dugan, S.; Barta, L.; Gordon, B.; Nguyen-Ho, C.; Pagel, P.S. Clinical Features of COVID-19 Infection in Patients Treated at a Large Veterans Affairs Medical Center. WMJ 2020, 119, 248–252. [Google Scholar] [PubMed]
415 Patients | |
---|---|
N° (%) of males | 259 (62%) |
Age, years, median (IQR) | 60 (24) |
N° (%) of patients in different age classes, (years) | |
18–29 | 21 (5%) |
30–39 | 40 (10%) |
40–49 | 62 (15%) |
50–59 | 79 (19%) |
60–69 | 98 (23%) |
70–80 | 74 (18%) |
>80 | 41 (10%) |
Days of enrolment after onset of symptoms, Median (IQR) | 6 (6.25) |
N° (%) of healthcare workers | 68/224 (30%) |
N° (%) of subjects with contact with a confirmed or suspected COVID-19 case | 129 (31%) |
Charlson comorbidity index, median (IQR) | 2 (0) |
N° (%) of subjects with underlying chronic disease | 230 (55%) |
| 164 (40%) |
| 87 (21%) |
| 59 (15%) |
| 33 (8%) |
| 32 (8%) |
| 52 (13%) |
| 6 (2%) |
N° (%) of asymptomatic subjects | 13/405 (3.1%) |
N° (%) of symptomatic subjects | 392/405 (94.4%) |
N° (%) of subjects in home isolation | 77(19%) |
N° (%) of hospitalized patients | 338 (81%) |
In-Home Isolation | Hospitalized | p | |
---|---|---|---|
N° of subjects | 77 | 338 | |
N° (%) of males | 42/77 (55%) | 217/338 (64%) | <0.01 |
Age, years, median (IQR) | 45 (19) | 62 (22) | <0.01 |
N° (%) of patients in different age classes, (years) | |||
18–29 | 12 (16%) | 9 (2%) | <0.01 |
30–39 | 14 (18%) | 26 (7%) | <0.01 |
40–49 | 22 (29%) | 40 (12%) | <0.01 |
50–59 | 13 (17%) | 66 (20%) | 0.23 |
60–69 | 14 (18%) | 84 (25%) | 0.21 |
70–80 | 1 (1%) | 73 (22%) | <0.01 |
>80 | 1 (1%) | 40 (12%) | <0.01 |
Days of enrolment after onset of symptoms, Median (range) | 5 | 6 | 0.32 |
N° (%) of healthcare workers | 24/48 (50%) | 44/176 (25%) | <0.01 |
N° (%) of subjects with contact with suspected or confirmed COVID-19 case | 30/54 (39%) | 128/204 (38%) | 0.27 |
Charlson comorbidity index, median (IQR) | 0 (2) | 6 (3) | <0.01 |
N° (%) of subjects with underlying chronic disease | 28/75 (36%) | 198/333 (59%) | <0.01 |
| 21/75 (27%) | 141/297 (42%) | <0.01 |
| 7/75 (9%) | 79/307 (23%) | <0.01 |
| 3/75 (4%) | 55/309 (16%) | <0.01 |
| 0/77 | 31/310 (9%) | <0.01 |
| 3/75 (4%) | 29/300 (9%) | 0.12 |
| 3/75(4%) | 48/309 (14%) | <0.01 |
| 0/77 | 6/274 (2%) | 0.19 |
N° (%) of asymptomatic subjects | 13/77 (17%) | 0/338 | <0.01 |
N° (%) of symptomatic patients | 64/77 (83%) | 338/338 (100%) | |
N° (%) of symptomatic subjects with | |||
| 43/76 (56%) | 171/208 (81%) | <0.01 |
| 35/76 (45%) | 113/210 (33%) | 0.25 |
| 3/76 (4%) | 83/210 (24%) | <0.01 |
| 27/76 (35%) | 35/160 (21.6%) | 0.03 |
| 26/76 (34%) | 73/169 (43.1%) | 0.19 |
| 6/76 (8%) | 23/192 (7%) | 0.33 |
| 2/76 (2%) | 0/338 | <0.01 |
Clinical presentation of COVID-19, N° (%) | |||
| 77 | 199 (61) * | <0.01 |
| 0 | 129 (39) * | <0.01 |
| 0 | 59 (14%) | <0.01 |
p Value | OR | 95% C.I. | ||
---|---|---|---|---|
Lower Limit | Upper Limit | |||
Age | <0.01 | 0.96 | 0.94 | 0.98 |
Sex | 0.72 | 0.89 | 0.49 | 1.64 |
Charlson Comorbidity Index | <0.01 | 0.66 | 0.54 | 0.82 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pisaturo, M.; De Angelis, G.; Maggi, P.; Sangiovanni, V.; Numis, F.G.; Gentile, I.; Masullo, A.; Rescigno, C.; Calabria, G.; Salomone Megna, A.; et al. Clinical Features of Patients with Home Isolation Sars-Cov-2 Infection: A Multicenter Retrospective Study in Southern Italy. Life 2021, 11, 347. https://doi.org/10.3390/life11040347
Pisaturo M, De Angelis G, Maggi P, Sangiovanni V, Numis FG, Gentile I, Masullo A, Rescigno C, Calabria G, Salomone Megna A, et al. Clinical Features of Patients with Home Isolation Sars-Cov-2 Infection: A Multicenter Retrospective Study in Southern Italy. Life. 2021; 11(4):347. https://doi.org/10.3390/life11040347
Chicago/Turabian StylePisaturo, Mariantonietta, Giulia De Angelis, Paolo Maggi, Vincenzo Sangiovanni, Fabio Giuliano Numis, Ivan Gentile, Alfonso Masullo, Carolina Rescigno, Giosuele Calabria, Angelo Salomone Megna, and et al. 2021. "Clinical Features of Patients with Home Isolation Sars-Cov-2 Infection: A Multicenter Retrospective Study in Southern Italy" Life 11, no. 4: 347. https://doi.org/10.3390/life11040347